Vincerx Pharma CMO Departs, Interim Appointed
Ticker: VINC · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | 8-K |
| Filed Date | Dec 27, 2024 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.0001, $13.66 m, $13.66 million, $20 m, $1,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, material-agreement
TL;DR
Vincerx Pharma CMO out, interim in. New deal signed.
AI Summary
On December 20, 2024, Vincerx Pharma, Inc. announced the departure of Dr. Michael R. Bristow from his role as Chief Medical Officer. The company also appointed Dr. David J. Bear as interim Chief Medical Officer. Additionally, Vincerx Pharma entered into a material definitive agreement, the details of which are not fully disclosed in this filing.
Why It Matters
The departure of a Chief Medical Officer and the appointment of an interim successor can signal changes in the company's strategic direction or research and development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in a pharmaceutical company, can introduce uncertainty regarding future development and strategy.
Key Players & Entities
- Vincerx Pharma, Inc. (company) — Registrant
- Dr. Michael R. Bristow (person) — Departing Chief Medical Officer
- Dr. David J. Bear (person) — Appointed Interim Chief Medical Officer
- December 20, 2024 (date) — Date of earliest event reported
FAQ
What is the reason for Dr. Michael R. Bristow's departure?
The filing does not specify the reason for Dr. Michael R. Bristow's departure as Chief Medical Officer.
Who has been appointed as the interim Chief Medical Officer?
Dr. David J. Bear has been appointed as the interim Chief Medical Officer.
What is the effective date of the reported events?
The earliest event reported is dated December 20, 2024.
What type of material definitive agreement did Vincerx Pharma enter into?
The filing indicates the entry into a material definitive agreement but does not provide specific details about its nature or terms.
Has Vincerx Pharma undergone any previous name changes?
Yes, Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. (name change effective 20201223) and LifeSci Acquisition Corp. (name change effective 20191206).
Filing Stats: 2,777 words · 11 min read · ~9 pages · Grade level 13.4 · Accepted 2024-12-27 16:13:59
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
- $13.66 m — d company upon the closing is less than $13.66 million, the Exchange Ratio will be adjus
- $13.66 million — adjusted to meet this minimum value of $13.66 million. The business combination contemplate
- $20 m — ed to be in an amount equal to at least $20 million, subject to increase with the wri
- $1,500,000 — rmined by Oqory are required to provide $1,500,000 in interim financing to the Company, of
- $750,000 — ncing to the Company, of which at least $750,000 will be provided following execution of
- $2.4 million — imates that it will incur approximately $2.4 million in costs primarily related to severance
- $0.001 — rice per share of Common Stock equal to $0.001 and is exercisable at any time and from
- $0.1839 — rice per share of Common Stock equal to $0.1839. Each Common Stock Warrant will be exer
- $0.9 million — enses, are expected to be approximately $0.9 million. The Company currently intends to use t
Filing Documents
- d875384d8k.htm (8-K) — 46KB
- d875384dex41.htm (EX-4.1) — 76KB
- d875384dex42.htm (EX-4.2) — 80KB
- d875384dex51.htm (EX-5.1) — 10KB
- d875384dex101.htm (EX-10.1) — 49KB
- d875384dex102.htm (EX-10.2) — 170KB
- d875384dex991.htm (EX-99.1) — 13KB
- d875384dex992.htm (EX-99.2) — 12KB
- 0001193125-24-285929.txt ( ) — 705KB
- vinc-20241220.xsd (EX-101.SCH) — 3KB
- vinc-20241220_lab.xml (EX-101.LAB) — 18KB
- vinc-20241220_pre.xml (EX-101.PRE) — 11KB
- d875384d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Pre-Funded Warrant 4.2 Form of Common Stock Warrant 5.1 Opinion of Pillsbury Winthrop Shaw Pittman LLP 10.1 Binding Term Sheet, as amended 10.2 Securities Purchase Agreement 99.1 Press Release dated December 27, 2024 99.2 Disclosures 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 27, 2024 VINCERX PHARMA, INC. By: /s/ Raquel E. Izumi Name: Raquel E. Izumi, Ph.D. Title: Acting Chief Executive Officer